Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: LTK007 who wrote (1871)	1/23/2002 4:10:13 PM
From: 613	Read Replies (1) \| Respond to of 2515

Stock price is no longer about Erbitux efficacy. Researchers' reputations speak for themselves. While not a cure, it does slow or halt tumor growth in a reasonable # of patients for approval. But with all that's happened, if new trials are needed or they get delayed a year (which is almost inevitable at this point), they lose their market edge and they will be just another drug on the market. They will make $ but not as much as before. So unless some sweetheart deal with the FDA can be worked out, stock will flounder in hype. Good for day traders. Risky for holders.